Journal of Yeungnam Medical Science

Eun-Jin Cheon

2 Articles

Hypertension and cognitive dysfunction: a narrative review: Eun-Jin Cheon; J Yeungnam Med Sci. 2023;40(3):225-232. Published online November 29, 2022; DOI: https://doi.org/10.12701/jyms.2022.00605

1,742 View
119 Download
2 Citations

Cognitive dysfunction is relatively less considered a complication of hypertension. However, there is sufficient evidence to show that high blood pressure in middle age increases the risk of cognitive decline and dementia in old age. The greatest impact on cognitive function in those with hypertension is on executive or frontal lobe function, similar to the area most damaged in vascular dementia. Possible cognitive disorders associated with hypertension are vascular dementia, Alzheimer disease, and Lewy body dementia, listed in decreasing strength of association. The pathophysiology of cognitive dysfunction in individuals with hypertension includes brain atrophy, microinfarcts, microbleeds, neuronal loss, white matter lesions, network disruption, neurovascular unit damage, reduced cerebral blood flow, blood-brain barrier damage, enlarged perivascular damage, and proteinopathy. Antihypertensive drugs may reduce the risk of cognitive decline and dementia. Given the high prevalence of dementia and its impact on quality of life, treatment of hypertension to reduce cognitive decline may be a clinically relevant intervention.

Citations

Citations to this article as recorded by

Chronic Neuroinflammation and Cognitive Decline in Patients with Cardiac Disease: Evidence, Relevance, and Therapeutic Implications
Jan Traub, Anna Frey, Stefan Störk
Life.2023; 13(2): 329. CrossRef
The A-to-Z factors associated with cognitive impairment. Results of the DeCo study
María Gil-Peinado, Mónica Alacreu, Hernán Ramos, José Sendra-Lillo, Cristina García, Gemma García-Lluch, Teresa Lopez de Coca, Marta Sala, Lucrecia Moreno
Frontiers in Psychology.2023;[Epub] CrossRef

Apathy syndrome in a patient previously treated with selective serotonin reuptake inhibitors for depression: Hye-Geum Kim, Bon-Hoon Koo, Seung Woo Lee, Eun-Jin Cheon; Yeungnam Univ J Med. 2019;36(3):249-253. Published online March 15, 2019; DOI: https://doi.org/10.12701/yujm.2019.00150

11,455 View
144 Download
3 Citations

Abstract PDF

There is considerable overlap in the clinical presentations of apathy and depression. However, differential diagnosis between apathy and other psychiatric conditions, including depression and dementia, is important. In this report, we present the case of a 67-year-old woman with a history of receiving selective serotonin reuptake inhibitor (SSRI) treatment for depression. Differential diagnosis between treatment-resistant depression and SSRI-induced apathy syndrome was required. The symptoms of her apathy syndrome were relieved after the discontinuation of SSRIs and the addition of olanzapine, methylphenidate, and modafinil. Furthermore, we briefly review related literature in this article.

Citations

Citations to this article as recorded by

Apathy associated with antidepressant drugs: a systematic review
Vasilios G. Masdrakis, Manolis Markianos, David S. Baldwin
Acta Neuropsychiatrica.2023; 35(4): 189. CrossRef
Can antidepressant use be associated with emotional blunting in a subset of patients with depression? A scoping review of available literature
Muhammad Youshay Jawad, Maurish Fatima, Umer Hassan, Zaofashan Zaheer, Muhammad Ayyan, Muhammad Ehsan, Muhmmad Huzaifa Ahmed Khan, Ahsan Qadeer, Abdul Rehman Gull, Muhammad Talha Asif, Mujeeb U. Shad
Human Psychopharmacology: Clinical and Experimental.2023;[Epub] CrossRef
Investigation of the efficiency of various antidepressant replacement regimens in the development of SSRI-induced apathy syndrome
V. E. Medvedev, R. A. Kardashyan, V. I. Frolova, A. M. Burno, S. V. Nekrasova, V. I. Salyntsev
Neurology, Neuropsychiatry, Psychosomatics.2020; 12(2): 48. CrossRef

Author index